Researchers have used a genetic engineering strategy to dramatically reduce levels of tau—a key protein that accumulates and becomes tangled in the brain during the development of Alzheimer’s disease—in an animal model of the condition.
- Prior known Alzheimer’s genes have been associated with amyloid accumulation and neuroinflammation.
- A cutting-edge technique known as whole genome sequencing was used to identify new, rare gene variants associated with Alzheimer’s disease.
- Findings could suggest new targets for drug development aimed at enhancing neuroplasticity and the stability of synapses.
Dmitry Prokopenko, PhD
This paper brings us to the next stage of disease-gene discovery by allowing us to look at the entire sequence of the human genome and assess the rare genomic variants, which we couldn’t do before.
McCance Center for Brain Health, Massachusetts General Hospital
BOSTON – In the first study to use whole genome sequencing (WGS) to discover rare genomic variants associated with Alzheimer’s disease (AD), researchers have identified 13 such variants (or mutations). In another novel finding, this study establishes new genetic links between AD and the function of synapses, which are the junctions that transmit information between neurons, and neuroplasticity, or the ability of neurons to reorganize the brain’s neural network. These discoveries could help guide development of new therapies for this devastating neurological condition. Researchers at Massachusetts General Hospital (MGH), the Harvard T. H. Chan School of Public Health, and Beth Israel Deaconess Medical Center report these findings in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association.
Over the last four decades, MGH has pioneered research on the genetic origins of AD, led by Rudolph Tanzi, PhD, vice chair of Neurology and director of the hospital’s Genetics and Aging Research Unit. Notably, Tanzi and colleagues co-discovered genes that cause early onset (prior to age 60) familial AD (that is, a form that runs in families), including the amyloid protein (A4) precursor (APP), and the presenilin genes (PSEN1 and PSEN2). Mutations in these genes lead to accumulation of amyloid plaques in the brain, a hallmark of AD.
The next 30 AD gene variants that were discovered are primarily linked to chronic inflammation in the brain (or neuroinflammation), which also increases the risk for this cognitive disease. However, loss of synapses is the neurological change that is most closely correlated with the severity of dementia in Alzheimer’s disease, yet no clear genetic links between the disease and these vital connections had previously been identified. “It was always kind of surprising that whole-genome screens had not identified Alzheimer’s genes that are directly involved with synapses and neuroplasticity,” says Tanzi.
Prior to this paper, the genome-wide association study (GWAS) was the primary tool used for identifying AD genes. In a GWAS, the genomes of many individuals are scanned in search of common gene variants that occur more frequently in people who have a given disease, such as AD. But to date, common Alzheimer’s-associated gene variants have accounted for less than half of the heritability of AD. A standard GWAS misses the rare gene variants (those occurring in less than 1% of the population), a problem solved by the WGS, which scans every bit of DNA in a genome.
“This paper brings us to the next stage of disease-gene discovery by allowing us to look at the entire sequence of the human genome and assess the rare genomic variants, which we couldn’t do before,” says Dmitry Prokopenko, PhD, of MGH’s McCance Center for Brain Health, who is lead author of the study.
Identifying less-common gene mutations that increase the risk for AD is important because they may hold critical information about the biology of the disease, says Tanzi. “Rare gene variants are the dark matter of the human genome,” he says, and there are lots of them: Of the three billion pairs of nucleotide bases that form a complete set of DNA, each person has 50 to 60 million gene variants—and 77% are rare.
In their quest to find rare AD gene variants, Tanzi, Prokopenko and their colleagues performed WGS analyses on the genomes of 2,247 individuals from 605 families that include multiple members who have been diagnosed with AD. They also analyzed WGS datasets on 1,669 unrelated individuals. The study identified 13 previously unknown rare gene variants associated with AD. Strikingly, these gene variants were associated with functioning of synapses, development of neurons, and neuroplasticity.
“With this study, we believe we have created a new template for going beyond standard GWAS and association of disease with common genome variants, in which you miss much of the genetic landscape of the disease,” says Tanzi, who sees potential for their methods to be used to study the genetics of many other conditions. Moreover, he plans to use “Alzheimer’s in a dish”—three-dimensional cell culture models and brain organoids he and his colleagues have developed over the past decade—to explore what happens when the rare mutations this paper identified are inserted in neurons. “That could help guide us in novel drug discovery,” says Tanzi.
Tanzi is the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard Medical School (HMS) and co-director of the McCance Center for Brain Health at MGH. Prokopenko is an instructor in Neurology at HMS.
This study was supported by the Cure Alzheimer’s Fund and grants from the National Institutes of Health.
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2020, Mass General was named #6 in the U.S. News & World Report list of "America’s Best Hospitals."
- Press Release
- Mar | 4 | 2021
A team at Massachusetts General Hospital and Harvard Medical School has developed an artificial intelligence–based method to screen currently available medications as possible treatments for Alzheimer’s disease.
- Press Release
- Sep | 17 | 2020
Development of an imaging probe to visualize Alzheimer's disease-related gamma-secretase in the brain
Scientists have developed a molecular imaging probe to reveal Alzheimer’s disease (AD)-related γ-secretase in rodents and macaques with translational potentials in humans.
- Press Release
- Jun | 22 | 2020
Different "Subtypes" of Alzheimer’s May be Linked to Different Modifications of the Tau Protein, Mass General-led Team Finds
A new study reveals a possible biological reason that Alzheimer’s Disease progresses at different rates in different patients.
- Press Release
- May | 27 | 2020
A new study suggests neurofilament light chain (NfL) has great potential as a biomarker for early detection of Alzheimer’s disease and could be also useful for monitoring treatment response for that condition.
- Press Release
- May | 11 | 2020
Mass General Researchers Link High Calcium Levels in Mitochondria to Neuronal Death in Alzheimer’s Disease
This relationship was previously documented in cell culture, but seeing this phenomenon in living mice makes it more likely that this occurs in people also and could point to a new target for Alzheimer’s disease.